PFIZER AND BIONTECH PROVIDE UPDATE ON ONGOING STUDIES OF COVID-19 VACCINE | Pfizer
NEW YORK and MAINZ, GERMANY, DECEMBER 17, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today shared that following a routine review by the external independent Data Monitoring Committee (DMC), the companies will amend the clinical study evaluating the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months to under 5 years of age.
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-ongoing-studies-covid-19